Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
暂无分享,去创建一个
D. Boll | K. Lindemann | C. Marth | P. Ottevanger | S. Polterauer | C. Høgdall | Ulla-Maija Haltia | E. Van Nieuwenhuysen | K. K. Andersen | K. Aro | M. Abreu | H. Lassus | J. Korach | T. Schnack | A. W. Ekmann-Gade | Maria de Lurdes Batarda | Jesper Hansen | Ala Jabri Haug | Karoliina M. Aro
[1] M. Bernardini,et al. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma. , 2021, Gynecologic oncology.
[2] M. Friedlander,et al. 392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study , 2020 .
[3] I. Vergote,et al. 18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial , 2020, Oral Plenary.
[4] M. Friedlander,et al. 234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 , 2020, Annals of Oncology.
[5] A. Oza,et al. 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 , 2020 .
[6] S. Pignata,et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] F. Marmé,et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.
[8] B. Monk,et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.
[9] M. Morgan,et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.
[10] Danielle M. Enserro,et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Timmerman,et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Ledermann,et al. ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease , 2019 .
[13] A. Oza,et al. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations , 2019, Cancers.
[14] C. Høgdall,et al. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB‐IIIC vs stage IV epithelial ovarian cancer after primary surgery , 2018, Acta obstetricia et gynecologica Scandinavica.
[15] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.
[16] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[17] Y. Drew,et al. Homologous recombination deficiency and ovarian cancer. , 2016, European journal of cancer.
[18] G. Shapiro,et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.
[19] Jacobus Pfisterer,et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.
[20] Jacobus Pfisterer,et al. A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.
[21] G. Mills,et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.